LAG3 Protein (Fc Tag)

Catalog No. ABIN1344459

Product Details

Target: LAG3 (Lymphocyte-Activation Gene 3 (LAG3))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human, Mouse, Monkey

Source: CHO Cells

Purification tag / Conjugate: This LAG3 protein is labelled with Fc Tag.

Application: SDS-PAGE (SDS), Flow Cytometry (FACS)

Purpose: LAG-3 (human):Fc (human) (rec.)

Specificity: Binds to human, mouse and monkey MHC class II.

Cross-Reactivity: Human, Monkey, Mouse

Characteristics: The sequence coding for the 4 extracellular Ig-like domains of human LAG-3 (D1-D4) is fused to the Fc portion of human IgG1.

Purity: >99 % (SDS-PAGE)

Endotoxin Level: <0.001EU/μg purified protein (LAL test).

Biological Activity Comment: Inhibits binding of MAb to LAG-3 (human) to LAG-3. Induces maturation of human dendritic cells.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: In PBS containing 5 mM arginine.

Handling Advice: After opening, prepare aliquots and store at -20 °C. Avoid freeze/thaw cycles. PBS containing at least 0.1 % BSA should be used for further dilutions.

Storage: 4 °C,-20 °C

Storage Comment:

Short Term Storage: +4°C

Long Term Storage: -20°C

Use & Stability: Stable for at least 6 months after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. Contains arginine for optimized protein stability.

Expiry Date: 6 months

References

Brignone, Grygar, Marcu, Schäkel, Triebel: "A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 179, Issue 6, pp. 4202-11, (2007) (PubMed).

Triebel, Hacene, Pichon: "A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors." in: Cancer letters, Vol. 235, Issue 1, pp. 147-53, (2006) (PubMed).

Buisson, Triebel: "LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors." in: Immunology, Vol. 114, Issue 3, pp. 369-74, (2005) (PubMed).

Andreae, Piras, Burdin, Triebel: "Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223)." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 168, Issue 8, pp. 3874-80, (2002) (PubMed).

Huard, Prigent, Pagès, Bruniquel, Triebel: "T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding." in: European journal of immunology, Vol. 26, Issue 5, pp. 1180-6, (1996) (PubMed).

Huard, Prigent, Tournier, Bruniquel, Triebel: "CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins." in: European journal of immunology, Vol. 25, Issue 9, pp. 2718-21, (1995) (PubMed).

Target Details

Target: LAG3 (Lymphocyte-Activation Gene 3 (LAG3))

Alternative Name: LAG-3 (LAG3 Products)

Background:

Lymphocyte Activation Gene-3, FDC Protein, CD223

Lymphocyte activation gene 3 (LAG-3, CD223) plays an important role in negatively regulating T cell proliferation, function and homeostasis. It is required for maximal natural and induced regulatory T cell (Treg) function. LAG-3 is closely related to the T cell co-receptor CD4 and binds to MHC class II molecules but with a significantly higher affinity than CD4.

Molecular Weight: ~80kDa (SDS-PAGE)

UniProt: P18627

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints